Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Volker A. Erdmann, Jan Barciszewski, editors.
    Summary: DNA and RNA nanobiotechnologies have currently reached the status of one of the most dynamic research areas in the field of drug delivery in molecular medicine. Scientists and bio-engineers are creating totally new nanometer-scale structures with unique biological properties for a wide range of medical applications. The book, written by world-leading scientists in this new field, gives an overview of various aspects and applications of DNA and RNA nanotechnologies. These include the design and synthesis of DNA and RNA nanostructures with the aim of using them for different kinds of drug deliveries, for genetic immunization, for metabolite and nucleic acid detection, gene regulation, siRNA delivery for cancer treatment, and even analytical and therapeutic applications of aptamer-based nanoparticles. This volume will be of interest not only to graduate students and researchers in the field of molecular medicine and molecular biology, but also to chemists interested in the biological fields. As a matter of fact, the book contains so many new and unique approaches to this area of molecular medicine that it may inspire the interested reader to undertake research into nucleic acid nanotechnologies.

    Contents:
    Introduction
    RNA Nanotechnology: methods for synthesis, conjugation, assembly and application of RNA nanoparticles
    Adsorption of double-stranded DNA to graphene oxide preventing enzymatic digestion
    Electrogenerated chemiluminescence of conjugated polymer films from patterned electrodes
    Use of RNA structure flexibility data in nanostructure modeling
    Informatic resources for identifying and annotating structural RNA motifs
    A nanostructure made of a bacterial noncoding RNA
    HAPIscreen, a method for high-throughput aptamer identification
    Characterization of photophysical and base-mimicking properties of a novel fluorescent adenine analogue in DNA
    Bifacial nucleoside as a surrogate for both T and A in duplex DNA
    Functionally important structural elements of U12 snRNA
    Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes
    Automatic molecular weaving prototyped by using single-stranded DNA
    Nucleic Acid Aptamers: Clinical Applications and Promising New Horizons
    Nanotextured Substrates With Immobilized Aptamers for Cancer Cell Isolation and Cytology
    Targeting cancer with peptide aptamers
    Synthetic, biofunctional nucleic acid-based molecular devices
    Inducible site-selective bottom-up assembly of virus-derived nanotube arrays on RNA-equipped wafers
    Special delivery: targeted therapy with small RNAs, RNAi nanomedicines: challenges and opportunities within the immune system
    Pyrene-functionalized oligonucleotides and locked nucleic acids (LNAs): Tools for fundamental research, diagnostics, and nanotechnology
    Stabilizing RNA by the sonochemical formation of RNA nanospheres. Sonochemical synthesis of DNA nanospheres
    Nucleic acid based molecular devices
    Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study
    A sol-gel-based microfluidics system enhances the efficiency of RNA aptamer selection
    Hierarchical nanotextured microelectrodes overcome the molecular transport barrier to achieve rapid, direct bacterial detection
    Recent developments in lipid-based pharmaceutical nanocarriers
    Targeted delivery of RNAi therapeutics for cancer therapy
    DNAsomes: Multifunctional DNA-based nanocarriers
    Reversible and Controllable Nanolocomotion of an RNA-Processing Machinery
    Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles
    A highly sensitive microRNA biosensor based on ruthenium oxide nanoparticle-initiated polymerization of aniline
    Preparation and high-resolution microscopy of gold cluster labeled nucleic acid conjugates and nanodevices
    Kinetically grafting G-quadruplexes onto DNA nanostructures for structure and function encoding via a DNA machine
    Synthesis of glycerol nucleic acid (GNA) phosphoramidite monomers and oligonucleotide polymers
    Cancer immunotherapy and nanomedicine
    RNA nanotechnology: inspired by DNA
    From nanotechnology to nanomedicine: applications to cancer research
    Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery
    Advances in novel drug delivery strategies for breast cancer therapy
    DNA origami: a history and current perspective
    Nanoparticles: a promising modality in the treatment of sarcomas
    Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication
    Recent developments in oligonucleotide conjugation
    In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers
    DNA and carbon nanotubes as medicine
    LHRH-targeted nanoparticles for cancer therapeutics
    Nanoparticle-aptamer conjugates for cancer cell targeting and detection
    Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches
    Prediction and design of DNA and RNA structures
    siRNA applications in nanomedicine.
    Digital Access Springer 2013
  • Article
    Scriver CR, Reade TM, DeLuca HF, Hamstra AJ.
    N Engl J Med. 1978 Nov 02;299(18):976-9.
    The serum concentration of 1,25-dihydroxylvitamin D (1,25-[OH]2D) in normal children and in children with inherited diseases of bone was compared by use of a competitive binding assay. Observed values were: in 12 normal children and adolescents, 37.1 +/- 1.9 pg per milliliter (mean +/- S.D.); in 14 patients with X-linked hypophosphatemic rickets treated with vitamin D2 and phosphate supplements, 15.6 +/- 7.8 (P less than 0.01 versus control); in six patients with autosomal recessive vitamin D dependency treated with vitamin D2, 9.5 +/- 2.9 (P less than 0.01 versus control); and in four untreated patients with autosomal dominant hypophosphatemic (non-rachitic) bone disease, 30.2 +/- 6.3 (not significantly different from the controls). The difference in bone disease between X-linked hypophosphatemia (severe) and hypophosphatemic bone disease (mild) at comparable low serum levels of phosphate implies that 1,25-(OH)2D and phosphate may have independent roles in the pathogenesis of defective bone mineralization.
    Digital Access Access Options